Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

• Published in: Alzheimer's research & therapy Vol. 14; no. 1; pp. 191 - 17
• Main Authors: McDade, Eric, Cummings, Jeffrey L., Dhadda, Shobha, Swanson, Chad J., Reyderman, Larisa, Kanekiyo, Michio, Koyama, Akihiko, Irizarry, Michael, Kramer, Lynn D., Bateman, Randall J.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.12.2022; BioMed Central; BMC
• Subjects: Alzheimer Disease - diagnostic imaging; Alzheimer Disease - drug therapy; Alzheimer's disease; Amyloid beta-Peptides; Amyloidogenic Proteins; Antibodies, Monoclonal, Humanized - therapeutic use; Biomarkers; Brain - diagnostic imaging; Cognition; Drug therapy; Humans; Monoclonal antibodies; Testing; United States

Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The objective of this analysis is to report results from study 201 blinded period (core),...